Legal & General Group Plc Continues to Hold Position in Teligent, Inc. (TLGT)
Legal & General Group Plc held its position in shares of Teligent, Inc. (NASDAQ:TLGT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,081 shares of the company’s stock at the end of the 2nd quarter. Legal & General Group Plc’s holdings in Teligent were worth $102,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of TLGT. Russell Investments Group Ltd. boosted its stake in Teligent by 124.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,043,046 shares of the company’s stock valued at $9,544,000 after purchasing an additional 577,635 shares in the last quarter. Vanguard Group Inc. boosted its stake in Teligent by 10.4% during the 1st quarter. Vanguard Group Inc. now owns 1,976,891 shares of the company’s stock valued at $15,440,000 after purchasing an additional 185,624 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new position in Teligent during the 1st quarter valued at $612,000. State of Wisconsin Investment Board bought a new position in Teligent during the 2nd quarter valued at $284,000. Finally, Aperio Group LLC bought a new position in Teligent during the 2nd quarter valued at $256,000. Hedge funds and other institutional investors own 66.34% of the company’s stock.
Shares of Teligent, Inc. (TLGT) opened at 6.46 on Friday. Teligent, Inc. has a 1-year low of $5.74 and a 1-year high of $9.54. The stock’s 50 day moving average price is $6.85 and its 200 day moving average price is $6.85. The company’s market capitalization is $344.91 million.
Teligent (NASDAQ:TLGT) last issued its earnings results on Tuesday, August 8th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.04). The business had revenue of $18.40 million for the quarter, compared to the consensus estimate of $20.11 million. Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The business’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 EPS. Analysts expect that Teligent, Inc. will post $0.07 EPS for the current year.
A number of equities analysts have issued reports on the company. Zacks Investment Research lowered Teligent from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $11.00 price target on shares of Teligent in a research note on Tuesday, August 8th. Roth Capital set a $9.00 price target on Teligent and gave the company a “buy” rating in a research note on Wednesday, August 23rd. BidaskClub lowered Teligent from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $9.00 price target (up from $8.00) on shares of Teligent in a research note on Monday, July 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $9.33.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.